CryoCath Technologies

CYT-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about CYT-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
May 7, 2008
Treats atrial fibrillation (irregular heartbeat). This is a large coming market in cardiac area that is unsolved. The clinical trials they are doing in the US and Europe are indicating that the doctors are really adopting the product. Will probably be the leading therapy in this area. Expecting a takeout, especially if they get FDA approval.
Show full opinionHide full opinion
Treats atrial fibrillation (irregular heartbeat). This is a large coming market in cardiac area that is unsolved. The clinical trials they are doing in the US and Europe are indicating that the doctors are really adopting the product. Will probably be the leading therapy in this area. Expecting a takeout, especially if they get FDA approval.
COMMENT
COMMENT
January 24, 2007
Has some experts telling him he should be looking at this again.
Show full opinionHide full opinion
Has some experts telling him he should be looking at this again.
HOLD
HOLD
January 13, 2005
As a medical device company its got its risks. The market they are in is not fully developed, so they need to clear the FDA hurdles, develop a market and hit their milestones. Arctic Circler(R) should be a very big piece of that. Expects to have some very good news in 05/06 on this.
Show full opinionHide full opinion
As a medical device company its got its risks. The market they are in is not fully developed, so they need to clear the FDA hurdles, develop a market and hit their milestones. Arctic Circler(R) should be a very big piece of that. Expects to have some very good news in 05/06 on this.
DON'T BUY
DON'T BUY
December 20, 2004
Just did a financing and the stock can't seem to get beyond the financing price. Unfortunately had to raise cash to get to the next level. Likes the product and the management team. Longer term, it's a good keeper, but doesn't expect a whole lot in the short term. Their US revenues have to ramp up before the market gets excited. Selling his position.
Show full opinionHide full opinion
Just did a financing and the stock can't seem to get beyond the financing price. Unfortunately had to raise cash to get to the next level. Likes the product and the management team. Longer term, it's a good keeper, but doesn't expect a whole lot in the short term. Their US revenues have to ramp up before the market gets excited. Selling his position.
HOLD
HOLD
December 17, 2004
Recently did a financing which is typical for a lot of biotech companies. Their research is very interesting. Trying to increase their marketing internationally.
Show full opinionHide full opinion
Recently did a financing which is typical for a lot of biotech companies. Their research is very interesting. Trying to increase their marketing internationally.
WEAK BUY
WEAK BUY
October 14, 2004
Using freezing instead of heat to treat injuries to the heart will be the big driver next year. Good technology that is being accepted. Long term should be good, but short term would be concerned about general market risk.
Show full opinionHide full opinion
Using freezing instead of heat to treat injuries to the heart will be the big driver next year. Good technology that is being accepted. Long term should be good, but short term would be concerned about general market risk.
BUY
BUY
September 24, 2004
Well managed and well financed. Takeover is a possibility.
Show full opinionHide full opinion
CryoCath Technologies (CYT-T)
September 24, 2004
Well managed and well financed. Takeover is a possibility.
VAGUE
VAGUE
September 7, 2004
The market is looking for more sales from this company.
Show full opinionHide full opinion
The market is looking for more sales from this company.
HOLD
HOLD
August 26, 2004
The value for stock will increase to 8 dollars. Therefore, hold the stocks.
Show full opinionHide full opinion
The value for stock will increase to 8 dollars. Therefore, hold the stocks.
WAIT
WAIT
July 30, 2004
Have a great noninvasive product to deal with heart problems. Have a new products in the pipeline. Good potential, but may be fully valued.
Show full opinionHide full opinion
Have a great noninvasive product to deal with heart problems. Have a new products in the pipeline. Good potential, but may be fully valued.
BUY
BUY
July 8, 2004
Have a better product for surgeons to cure ablation of the heart. Starting to ramp up with approval in Europe and the US. Next quarter is important as you want to see the hockey stick ramp continue.
Show full opinionHide full opinion
Have a better product for surgeons to cure ablation of the heart. Starting to ramp up with approval in Europe and the US. Next quarter is important as you want to see the hockey stick ramp continue.
BUY
BUY
June 28, 2004
Likes both the product and the space.
Show full opinionHide full opinion
Likes both the product and the space.
BUY
BUY
May 17, 2004
Making substantial progress. The procedure they do takes less time and it had 100% success rate. Starting to see surgeons adopt this. The company will ultimately be sold.
Show full opinionHide full opinion
Making substantial progress. The procedure they do takes less time and it had 100% success rate. Starting to see surgeons adopt this. The company will ultimately be sold.
BUY
BUY
April 22, 2004
In a very large and growing market. A technology that is getting more and more accepted. Expecting very large revenue growth out of them this year. New products coming out in the third quarter. Could eventually be a takeover target.
Show full opinionHide full opinion
In a very large and growing market. A technology that is getting more and more accepted. Expecting very large revenue growth out of them this year. New products coming out in the third quarter. Could eventually be a takeover target.
DON'T BUY
DON'T BUY
April 20, 2004
Medical device companies are a bit of a minefield because big boys like Abbott, Baxter, Johnson & Johnson control the purchasing through a hospital. Interesting technology. Using a lot of cash. Wait to see their numbers. A high risk situation.
Show full opinionHide full opinion
Medical device companies are a bit of a minefield because big boys like Abbott, Baxter, Johnson & Johnson control the purchasing through a hospital. Interesting technology. Using a lot of cash. Wait to see their numbers. A high risk situation.
Showing 1 to 15 of 23 entries

CryoCath Technologies(CYT-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for CryoCath Technologies is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CryoCath Technologies(CYT-T) Frequently Asked Questions

What is CryoCath Technologies stock symbol?

CryoCath Technologies is a OTC stock, trading under the symbol CYT-T on the (). It is usually referred to as or CYT-T

Is CryoCath Technologies a buy or a sell?

In the last year, there was no coverage of CryoCath Technologies published on Stockchase.

Is CryoCath Technologies a good investment or a top pick?

CryoCath Technologies was recommended as a Top Pick by Serge Depatie on 2008-05-07. Read the latest stock experts ratings for CryoCath Technologies.

Why is CryoCath Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CryoCath Technologies worth watching?

In the last year 0 stock analysts on Stockchase covered CryoCath Technologies. The stock is worth watching.

What is CryoCath Technologies stock price?

On , CryoCath Technologies (CYT-T) stock closed at a price of $.